ReviewMolecular & cellular oncology
The role of NF-κB in the pathogenesis of glioma.
Review in Molecular & cellular oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Global research status, hotspots and prospects of ferroptosis in glioma: a scientometric analysis.Frontiers in cellular neuroscience · 2025Pooled it
- The significance of miR-124 in the diagnosis and prognosis of glioma: A systematic review.PloS one · 2024Pooled it
- Expression of NF-κB Isoforms and IKK Complex Subunits Differs in Peripheral Blood Mononuclear Cells (PBMCs) of Patients with Meningiomas: A Pilot Study.Life (Basel, Switzerland) · 2026Article
- The Gut-Brain-Immune Axis in Glioma: Emerging Mechanisms and Therapeutic Opportunities.Cellular and molecular neurobiology · 2026Review
- Characterisation of the expression of P2X7 receptor, cancer stem cell markers and immunological mediators in human high-grade gliomas.BMC neuroscience · 2025Article
- Prognostic Significance ofBiology · 2025Article
- Anti-Metastatic Effects of Aprepitant on Glioblastoma Cells: Targeting the Substance P/Neurokinin-1 Pathway.Cancer medicine · 2025Article
- VOPP1::EGFR fusion is associated with NFκB pathway activation in a glioneural tumor with histological features of ganglioglioma.Acta neuropathologica communications · 2025Article
- The Role of the Gut Microbiota in Modulating Signaling Pathways and Oxidative Stress in Glioma Therapies.Cancers · 2025Review
- Beta-Caryophyllene Augments Radiotherapy Efficacy in GBM by Modulating Cell Apoptosis and DNA Damage Repair via PPARγ and NF-κB Pathways.Phytotherapy research : PTR · 2025Article
- Article
- Role of scaffold proteins in the heterogeneity of glioblastoma.Cell communication and signaling : CCS · 2024Review
- Microfluidic-Derived Docosahexaenoic Acid Liposomes for Targeting Glioblastoma and Its Inflammatory Microenvironment.ACS applied materials & interfaces · 2024Article
- Analysis of Circulating Plasma MicroRNA Profile in Low-Grade and High-Grade Glioma - A Cross-Sectional Study.F1000Research · 2024Article
- Targeting NF-κB signaling cascades of glioblastoma by a natural benzophenone, garcinol, viaFrontiers in chemistry · 2024Article
- Progress in Glioma Stem Cell Research.Cancers · 2023Review
- Dysregulation of inflammasome activation in glioma.Cell communication and signaling : CCS · 2023Review
- The Critical Role of RNA mCellular and molecular neurobiology · 2023Review
- Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Therapeutic Potential of Linearol in Combination with Radiotherapy for the Treatment of Glioblastoma In Vitro.International journal of molecular sciences · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of NF-κB affects multiple aspects of cancer biology including cell survival and resistance to treatment. Glioblastoma (GBM) is the most common primary malignant tumor of the brain in adults and is resistant to treatment. Recent studies have reported that NF-κB activation in GBM is widespread and have elucidated the underlying regulatory mechanisms. EGFR gene amplification and mutation are among the key genetic alterations in GBM, and aberrant EGFR signaling is a key activator of NF-κB in GBM. In this review we discuss the evidence for activation of NF-κB in GBM and the key signaling pathways involved. Substantial evidence suggests a role for NF-κB in the pathogenesis of GBM and its resistance to treatment, indicating that NF-κB pathways may be useful targets for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.